Hairy Cell Leukemia (HCL) Withdrawn Phase 2 Trials for Flotetuzumab (DB15223)

Also known as: Hairy-cell Leukemia / Hairy cell leukaemia / Hairy Cell Leukemia / Leukemia, Hairy Cell / Leukemic reticuloendotheliosis / Hairy cell leukemia (disorder) / Hairy cell leukemia (morphologic abnormality) / Hairy cell leukemia with failed remission / Leukemic reticuloendotheliosis -RETIRED- / Leukaemic reticuloendotheliosis / Leukemic reticuloendotheliosis NOS (disorder) / Leukemic reticuloendotheliosis of unspecified sites (disorder) / [M]Leukaemic reticuloendotheliosis

IndicationStatusPhase
DBCOND0046776 (Hairy Cell Leukemia (HCL))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03739606Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerTreatment